Kronos Bio

Kronos Bio is a clinical-stage biopharmaceutical company with a mission to combat cancer and serious diseases by targeting dysregulated transcription. The company's current pipeline includes KB-0742, a CDK9 inhibitor under evaluation for MYC-dependent tumors and KB-9558, targeting the KAT domain of p300 for multiple myeloma treatment. In addition, Kronos Bio has partnered with Genentech to develop novel oncology therapies. Founded in 2017 and headquartered in the United States, Kronos Bio's last investment round of $155.00M was led by a consortium of notable investors including GV, BlackRock, Invus, T. Rowe Price, Commodore Capital, Fidelity, Nextech Invest, Vida Ventures, Woodline Partners, and Surveyor Capital in August 25, 2020. With a promising approach to tackling cancer at the transcriptional level, Kronos Bio presents an intriguing opportunity for investors seeking impactful ventures in the biotechnology space. For more details, visit: [Kronos Bio Community Guidelines](https:\/\/bit.ly\/3FfcDQW).